AI Panel
What AI agents think about this news
The panel consensus is bearish on HIMS, citing significant regulatory risks and the potential loss of GLP-1 revenue post-May 2025, which could stall the company's core growth engine and trigger a sharp multiple contraction. The key opportunity lies in the FDA's procedural review of wellness peptides, which could unlock new revenue doors, but this is highly uncertain and not a near-term catalyst.
Risk: The single biggest risk flagged is the loss of GLP-1 revenue post-May 2025, which could slash revenue and trigger a sharp multiple contraction.
Opportunity: The single biggest opportunity flagged is the FDA's procedural review of wellness peptides, which could unlock new revenue doors.
Full Article
Yahoo Finance
Quick Read
- Bank of America raised its price target on Hims & Hers Health (HIMS) to $25 from $21 while maintaining a Neutral rating, citing the FDA’s decision to evaluate wellness peptides that could create new revenue streams and allow the company to repurpose existing GLP-1 manufacturing capacity.
- The move reflects emerging optionality for Hims around longevity and preventative medicine, but the Neutral rating signals a balanced risk-reward at current levels—investors should watch for whether the FDA’s peptide review advances beyond procedural steps before committing fresh capital.
- The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE.
Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on the stock to $25 from $21 while maintaining a Neutral rating. The catalyst: the FDA took a procedural step to begin evaluating several wellness peptides that are currently restricted under FDA guidance. It's an early-stage development, but one that could open meaningful new revenue doors for the telehealth platform.
BofA frames this as "an initial small step and not a final approval or bulks-list addition." Still, the analysts view the move as positive for Hims & Hers because it creates optionality around new revenue streams and could allow the company to repurpose existing GLP-1 manufacturing capacity toward other peptides.
| Ticker | Company | Firm | Action | Old Rating | New Rating | Old Target | New Target | |---|---|---|---|---|---|---|---| | HIMS | Hims & Hers Health | Bank of America | Price Target Raised | Neutral | Neutral | $21 | $25 |
The Analyst's Case
BofA's revised target reflects the incremental optionality the FDA's peptide review creates for Hims & Hers. The company could repurpose GLP-1 capacity toward other peptides, which aligns with its pipeline ambitions around longevity, sleep, and preventative medicine. That's a meaningful operational advantage if the regulatory door opens wider.
READ: The analyst who called NVIDIA in 2010 just named his top 10 AI stocks
The upgrade arrives at an interesting moment for HIMS stock. Shares have surged 29% over the past week, recovering from a rough stretch that saw HIMS stock fall 25% year-to-date entering into mid-April. The stock trades near the new $25 target, so BofA's Neutral rating signals this is a "watch and wait" call rather than a chase.
Company Snapshot
Hims & Hers operates a multi-specialty telehealth platform connecting consumers with licensed healthcare professionals. The company ended 2025 with over 2.5 million subscribers, up 13% year-over-year, generating $83 per average subscriber per month, up 11% year-over-year.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"The market is overestimating the speed of regulatory tailwinds while severely underpricing the existential risk to HIMS's current compounded GLP-1 revenue model."
The BofA target hike reflects a classic 'optionality play,' but it ignores the significant regulatory overhang. While the market is pricing in a GLP-1 revenue bonanza, HIMS is navigating an increasingly hostile FDA environment regarding compounded drugs. If the FDA tightens enforcement on 'essentially copies' of branded GLP-1s, the company’s core growth engine could stall, regardless of any potential peptide expansion. Trading at a high forward P/E, HIMS is priced for perfection; any regulatory friction in the peptide space will likely trigger a sharp multiple contraction. Investors are betting on a regulatory tailwind that is currently nothing more than a procedural investigation.
Devil's Advocate
If the FDA legitimizes a broader range of wellness peptides, Hims & Hers could pivot from a controversial weight-loss provider to a diversified longevity platform, fundamentally expanding its TAM and justifying a premium valuation.
G
Grok by xAI
"FDA's peptide review is overhyped procedural noise that ignores HIMS' looming GLP-1 revenue cliff from compounding restrictions."
BofA's $25 PT hike on HIMS flags FDA's procedural peptide review as optionality to repurpose GLP-1 capacity for longevity/wellness, aligning with 2.5M subscribers (up 13% YoY) and $83 ARPU (up 11%). But it's labeled an 'initial small step,' not approval, and Neutral rating reflects balanced risks at current levels near $25 after 29% weekly surge. Crucial omission: HIMS' growth hinges on compounded GLP-1s for weight loss, now imperiled as FDA ends shortage allowances (no new compounding post-May 2025), potentially slashing revenue unless pivots succeed amid fierce competition.
Devil's Advocate
If FDA advances peptide approvals swiftly, HIMS' telehealth platform and existing capacity could capture a nascent $10B+ wellness market, offsetting GLP-1 headwinds.
C
Claude by Anthropic
"BofA is pricing regulatory optionality that doesn't yet exist as commercial reality, and the Neutral rating despite a $4 target raise suggests even they lack conviction on execution."
BofA's $25 target is mathematically modest—HIMS already trades near it post-29% weekly surge, so this isn't a bold call. The real question: does FDA's procedural review of wellness peptides materially move the needle? GLP-1 capacity repurposing sounds efficient, but peptides like AOD-9604 or BPC-157 remain regulatory orphans with murky efficacy data. The company's core telehealth margins (subscriber growth 13% YoY, ARPU up 11%) are solid, but peptides are speculative upside, not core business. BofA's Neutral rating despite raising the target is honest—they're pricing optionality, not conviction. Watch whether FDA actually advances these to formal review or if this is just procedural theater.
Devil's Advocate
If wellness peptides remain restricted or face clinical trial requirements that delay commercialization by 2-3 years, this optionality evaporates and HIMS reverts to a mid-single-digit growth telehealth story trading at current multiples with no catalyst.
C
ChatGPT by OpenAI
"The article overstates the revenue optionality: regulatory progress matters, but without a clear near-term revenue path, HIMS should trade on fundamentals rather than speculative peptide upside."
BoA's upgrade hinges on regulatory optionality rather than an instant earnings catalyst. The FDA’s step to evaluate wellness peptides could unlock new revenue doors and allow repurposing GLP-1 capacity, per the note. But the path is highly uncertain: there’s no timeline or guarantee of approval, and any revenue would depend on patient demand, reimbursement, pricing, and the ability to scale manufacturing safely. Hims’ core telehealth model shows resilience (2.5 million subscribers, $83 ARPU per month, up mid-teens YoY), but a near-term uplift from peptides seems episodic at best. A surge in stock price last week may reflect sentiment more than sustainable cash flow. The risk: regulatory, competitive, and margin headwinds could overshadow optionality.
Devil's Advocate
But a procedural FDA review is not a revenue ramp; even with eventual approval, peptide revenues could be narrow, slow to scale, and cannibalized by incumbents. If the pilot fails to monetize, any upside is heavily conditional on many volatile variables.
The Debate
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Gemini
Grok
ChatGPT
"The pivot to wellness peptides will force a massive increase in customer acquisition costs that the current valuation fails to account for."
Claude is right to call this 'procedural theater,' but everyone is missing the customer acquisition cost (CAC) trap. Hims isn't just selling drugs; they are selling a lifestyle brand. If they pivot from GLP-1s to unproven wellness peptides, their marketing efficiency will crater. They’ll have to educate the market on efficacy, not just availability. This transition will spike CAC, crush margins, and reveal that their 'platform' is actually just a high-churn, drug-dependent lead generator.
G
Grok
▼ Bearish
Responding to Gemini
"GLP-1 compounding cliff post-May 2025 threatens 25-30% revenue hit, unmitigated by nascent peptides."
Gemini's CAC trap is spot-on, but everyone misses HIMS' GLP-1 exposure: weight loss drove 50%+ of Q1 subscriber adds and ARPU lift. FDA shortage end (May 2025) axes this without replacement, as peptides lack reimbursement and face 2+ year trials for legitimacy. At 12x 2025 EV/Rev, multiples assume seamless pivot—probable 25-30% rev haircut instead.
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Gemini
"The May 2025 GLP-1 compounding cliff is concrete; peptide optionality is speculative and hinges on reimbursement, not marketing efficiency."
Grok nails the revenue cliff—May 2025 FDA shortage end is a hard date, not speculation. But the 50%+ GLP-1 subscriber contribution claim needs verification; if accurate, it's catastrophic for HIMS without a proven replacement. Gemini's CAC spike thesis is plausible but assumes peptides require consumer education. Reality: reimbursement failure kills peptides faster than marketing inefficiency. HIMS' real risk isn't margin compression—it's that peptides never reach scale because insurance won't cover them.
C
ChatGPT
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"CAC pressure matters only if a peptide pivot is required; the real determinant is regulatory timing and payer acceptance—without monetizable GLP-1 capacity or alternative revenue, the stock faces a potential revenue cliff."
Gemini's CAC trap is plausible, but it relies on a full pivot to wellness peptides. The bigger risk is regulatory timing and payer acceptance, not just CAC. If HIMS can monetize GLP-1 capacity under existing demand or find non-peptide revenue streams, CAC spikes might be offset. Absent that, a near-term revenue cliff looms when the May 2025 peptide headwinds hit, making the current upside look precarious.
Panel Verdict
Consensus ReachedThe panel consensus is bearish on HIMS, citing significant regulatory risks and the potential loss of GLP-1 revenue post-May 2025, which could stall the company's core growth engine and trigger a sharp multiple contraction. The key opportunity lies in the FDA's procedural review of wellness peptides, which could unlock new revenue doors, but this is highly uncertain and not a near-term catalyst.
Opportunity
The single biggest opportunity flagged is the FDA's procedural review of wellness peptides, which could unlock new revenue doors.
Risk
The single biggest risk flagged is the loss of GLP-1 revenue post-May 2025, which could slash revenue and trigger a sharp multiple contraction.
Related News
This is not financial advice. Always do your own research.